Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial
Metabolism and Target Organ Damage · 16.03.2026 · 6 (1)
DOI: 10.20517/mtod.2025.210 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 16.03.2026. Verfasst von Weihan Zhang und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Aim
This study investigated the effects of semaglutide combined with metformin on body weight, glucose and lipid metabolism, sex hormone levels, menstrual cyclicity, and psychological parameters of women living with polycystic ovary syndrome (PCOS)-related infertility and overweight/obesity.
Methods
Sixty-four patients living with infertility and PCOS [body mass index (BMI) ≥ 24 kg/m2] were randomly assigned to standard (n = 32) or semaglutide-intensified treatment groups (n = 32). Both groups underwent lifestyle modification interventions. The standard group received metformin monotherapy [500 mg three times daily (TID)] for 12 weeks, whereas the semaglutide-intensified treatment group received metformin and semaglutide for 12 weeks. An 8-week washout period followed treatment.
Results
The semaglutide-intensified treatment group showed a higher percentage of patients with restored menstrual cycles (86.87% vs. 60.00%, P = 0.038). Significant reductions in luteinizing hormone (LH), androgen levels, and the LH/follicle-stimulating hormone ratio were observed. Greater reductions were also noted in BMI, waist and hip circumference, absolute weight loss, body fat percentage, fasting plasma glucose, fasting insulin, and Homeostatic Model Assessment of Insulin Resistance (P < 0.05). No significant differences were observed in total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels. Psychological distress was not exacerbated in the semaglutide-intensified treatment group.
Conclusion
In women living with PCOS-related infertility and overweight/obesity, semaglutide combined with metformin provided superior improvements in weight reduction, glucose metabolism, insulin sensitivity, and menstrual cyclicity compared with metformin monotherapy, without exacerbating psychological distress. These findings suggest that semaglutide represents a promising therapeutic option for the clinical management of this population.
Zitieren
APA
Zhang, W., Xue, J., Wang, J., Ni, D., Zhou, W., Wang, B., Shi, J., & Wang, A. (2026). Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial. Metabolism and Target Organ Damage, 6(1). https://doi.org/10.20517/mtod.2025.210
Vancouver
Zhang W, Xue J, Wang J, Ni D, Zhou W, Wang B, et al. Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial. Metabolism and Target Organ Damage. 2026;6(1). doi:10.20517/mtod.2025.210
BibTeX
@article{Zhang2026,
author = {Zhang, Weihan and Xue, Jing and Wang, Jianjun and Ni, Dongdong and Zhou, Wenjing and Wang, Bin and Shi, Jinyi and Wang, Aihong},
title = {Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial},
journal = {Metabolism and Target Organ Damage},
year = {2026},
volume = {6},
number = {1},
doi = {10.20517/mtod.2025.210}
}
EUVIMED